Table 1 Data of patients enrolled in the study
No | Age | Sex | Primary tumor | Measurement of disease | Metastases | Therapy between primary surgery and start of diet |
|---|---|---|---|---|---|---|
1 | 47 | f | Ovarian cancer | CT, CA 125 | LI, LN, PC | 10 × Taxol/Carboplatin; 10 × Hycamptin |
2 | 46 | f | Breast Cancer | PET | MPE, AS | Radiatio, 6 × [CMF]; 12 × [Epirubicin/Cyclophosphamid[, 14 × [Taxotere[, 2 × [Gemcetabine] |
3 | 48 | f | Granulosa cell tumor | CT, PET, Inhibin | LI, MI | 6 × [Carboplatin/Epirubicin/Cyclophosphamid], 3 × Hemihepatectomy |
4 | 30 | f | Parotis carcinoma | CT | LO | Multiple surgery; Radiation; 6 × [Paclitaxel/Cisplatin] |
5 | 62 | f | Ovarian Cancer | US, CA 125 | PC, FIGO IV | ? × [Taxol/Carboplatin] |
6 | 38 | f | Osteosarcoma (jaw) | CT | LO | Multiple surgery |
7 | 51 | m | Oesophagus carcinoma | CT | LI, LN, MPE | 2 × [Radiotherapy+Cisplatin/5-FU]; 2 × [Cisplatin/5-FU]; 7 × [Doxotaxel] |
8 | 65 | f | Pancreas carcinoma | MRI | LI | 6 × [Gemcetabine], Immunotherapy (Survivin) |
9 | 33 | m | Thyroid carcinoma | US, CT, Calcitonin | LI, BO | Sanostatin, Interferon |
10 | 50 | m | Pancreas carcinoma | PET | LI | CapRI-Study branch A (Radiotherapy, Cisplatin/5-FU, IFN-alpha) |
11 | 64 | f | Thyroid carcinoma | CT, TG | LU, LN | Radio-Jod Therapy, Sanostatin |
12 | 42 | f | Colon carcinoma | PET | LI, LU | 6 × Radiotherapie (38,6 GBq I-131); Avastin; ? × [Cisplatin/Carboplatin] |
13 | 54 | f | Endometrial cancer | CT | LI, PC, AS | 8 × [Cisplatin/Adriamycin]; 2 × [Adriamycin/Doxorubicin]; 6 × [Navelbine/Carboplatin] |
14 | 60 | f | Lung cancer | PET | LI | 6 × [Carboplatin/Cisplatin/Etoposid] |
15 | 62 | m | Stomach cancer | PET | LI, PE, AS | 1 × [Irinothekan/5-FU/Folinacid]; 5 × [Etoposid/5-FU/Folinacid] |
16 | 54 | f | Ovarian cancer | CA 125 | PC, AS, Figo IIIC | ? × [Taxol/Carboplatin] |